Which Dry Binder Level Prevents Niclosamide Tablet Capping at Rotary Press Speeds?

In companion animal cestode control, tablet cores containing 50–70% w/w niclosamide are vulnerable to capping when direct compression is attempted on rotary presses because the API has low aqueous solubility, reported below 0.1 mg/mL at 25°C in unbuffered water, high elastic recovery, and a tendency to form layered agglomerates. A 500 mg label claim tablet with 800 mg total core mass is manufactured by high-shear wet granulation using 3–5% w/w povidone K30 as dry binder, 2–4% w/w croscarmellose sodium as disintegrant, and lactose monohydrate/microcrystalline cellulose as filler to 100%. The granulation endpoint is controlled by impeller power draw in a 25 L high-shear granulator; granule moisture is adjusted to 8–12% w/w before drying in a fluidized-bed dryer with 55–65°C inlet air to ≤2.0% w/w loss on drying per Ph. Eur. 2.2.32. Compression on a 27-station rotary press with 9 mm flat-faced beveled punches and 8–14 kN compression force gives tablets with hardness 60–90 N; friability is controlled to ≤1.0% per Ph. Eur. 2.9.7. Capping is observed at press speeds above 30 rpm when the dry binder falls below 3% w/w, while excessive binder above 5% w/w slows disintegration beyond 15 min. Dissolution testing uses Ph. Eur. 2.9.3 apparatus II at 50 rpm in 900 mL of 0.1 M hydrochloric acid with 0.5% w/v sodium lauryl sulfate; the acceptance window is ≥75% label release at 45 min. Regulatory compliance is anchored to VICH GL11 for impurity thresholds and VICH GL18 for residual solvent control. Finished dosage types include 125 mg, 250 mg, 500 mg, and 1000 mg flavored tablets in PVC/PVDC-aluminum blisters with desiccant; the package protects against hardness loss at 40°C/75% RH over 6 months. The formulation addition ratio is 62.5% w/w for the 500 mg strength but is reduced to 50% w/w at the 125 mg strength to maintain flow and compaction. Niclosamide has no meaningful activity against nematodes; therefore, tablets are not indicated for roundworm-only labels unless combined with a compatible anthelmintic in a fixed-dose product.

In ovine and caprine feed medication programs targeting Moniezia expansa and Moniezia benedeni, niclosamide is first converted into a 5–20% w/w intermediate premix on calcium carbonate or lactose monohydrate carrier. A 10% w/w premix is applied at 1–2 kg per 1000 kg finished ration, yielding 100–200 mg niclosamide per kg feed; published veterinary formularies list a 50–100 mg/kg bodyweight oral dose for ruminants, but the final label is controlled by national registration dossiers. The premix is produced in a 500 L ribbon blender at 12–15 rpm for 10–15 min after the API has been pre-sieved through a 250 µm screen. Homogeneity is validated by ISO 6497 sampling of animal feeding stuffs, with acceptance at relative standard deviation ≤5.0% over 10 sampling points. The production hall is maintained at 40–50% RH and 18–22°C; above 60% RH, the API’s electrostatic charge increases and material adheres to the blender walls, producing assay bias in later batches. Finished premix types include 5 kg, 10 kg, and 25 kg multi-wall paper bags with inner polyethylene liner, plus 20 kg fiber drums for export. Relevant compliance standards are VICH GL18 for residual solvents, Ph. Eur. 2.2.32 for loss on drying, and Regulation (EU) 2019/6 for veterinary medicinal premix registration. The following matrix summarizes the release testing used for the premix.

No injectable solution is produced from the premix; the only liquid downstream format in this segment is an oral drench suspension prepared as a separate viscosity-controlled formulation rather than diluted extemporaneously from premix powder.

When Anoplocephala Control Moves from Paste to Granulated Premix

For equine tapeworm control against Anoplocephala perfoliata and Anoplocephala magna, niclosamide is formulated into dry granules rather than simple powder blends because above 30% w/w the API exhibits high dusting potential and poor flow. A 25% w/w granule batch containing 2.5 g niclosamide per 10 g sachet is manufactured by dry granulation on a 300 kg/h roller compactor with 80 kN roll force and 1.0–1.5 mm sieve milling. Dry granulation is selected over aqueous wet granulation because the low water solubility of niclosamide causes non-uniform drug migration during tray drying from aqueous slurries. Granule flow is tested per Ph. Eur. 2.9.12; bulk and tapped density are measured per Ph. Eur. 2.9.34, with Carr index maintained at ≤25 before sachet filling. Finished product types include 10 g, 20 g, and 40 g foil-lined sachets, as well as 50 mL oral paste syringes containing 250 mg/g niclosamide dispersed in a non-aqueous base. Paste manufacturing is performed in a 100 L vacuum planetary mixer at –0.8 bar and 25–35 rpm; the base contains medium-chain triglycerides and 3–5% w/w fumed silica to control sedimentation. Compliance for single-dose sachets is demonstrated by Ph. Eur. 2.9.5 uniformity of mass, and impurity control follows VICH GL11. Because niclosamide has reported photodegradation sensitivity, packaging uses UV-resistant laminate and stability protocols include ICH Q1B photostability testing. The addition ratio of 25% w/w in granules corresponds to a 50 mg/kg dose for a 500 kg horse as described in older equine formulary compilations; however, country-specific prescribing information may restrict the use of the finished product to non-food horses only.

Powder-in-bottle formulations for companion animal oral suspension use a different particle-size specification than tablet granulations because sedimentation and resuspendability are the primary failure modes. A 100 mg/mL suspension for dogs and cats contains 10% w/v niclosamide, 0.2–0.5% w/v xanthan gum, 0.1% w/v sodium benzoate, and 0.05% w/v citric acid in purified water. Above 15% w/v niclosamide, the sediment height ratio after 24 hours falls below 0.8, and resuspendability exceeds 20 manual shakes. A rotor-stator disperser at 3000 rpm for 20 min reduces the median particle size from 45 µm to 15–25 µm as measured by laser diffraction per ISO 13320. Viscosity is maintained at 400–800 mPa·s by ISO 2555 rotational viscometry or Ph. Eur. 2.2.10. Microbiological quality follows Ph. Eur. 5.1.4, and preservative efficacy follows Ph. Eur. 5.1.3. Finished product types include 50 mL, 100 mL, and 200 mL amber polyethylene terephthalate bottles with child-resistant closures and low-density polyethylene adaptors; fill volume tolerance is ±3.0% per Ph. Eur. 2.9.27. The production line uses an in-line vacuum deaerator to avoid air bubbles during filling. This liquid format supports weight-based dose adjustment in cats and small dogs, where tablet splitting creates unacceptable dose deviations. Injectable aqueous vehicles are not considered an equivalent downstream option because the API’s limited solubility in aqueous media at physiological pH prevents reliable therapeutic concentration in a parenteral product; published data for this specific configuration is limited.

Ruminant Oral Drench Suspension Viscosity Drift and High-Shear Recirculation

Oral drench suspensions for cattle and sheep are manufactured as higher-viscosity, higher-concentration dispersions than companion animal suspensions. A 250 mg/mL drench uses 25% w/v niclosamide, 0.6–1.0% w/v xanthan gum, 0.2% w/v sodium benzoate, and 0.1% w/v simethicone emulsion to control foaming during recirculation. The addition ratio is set by wetting limitations: below 0.5% w/v surfactant, the API cannot be fully deagglomerated, while above 1.2% w/v surfactant the suspension degasses slowly and fills below target weight. Manufacturing uses a 500 L high-shear recirculation system with a 15 kW rotor-stator head operating at 2500 rpm and a 0.5 mm radial gap; milled API is added through a vacuum induction hopper to prevent dust exposure. Viscosity is controlled between 800–1500 mPa·s at 20°C per Ph. Eur. 2.2.10. A production bottleneck is viscosity drift during storage in polyethylene containers: low-density polyethylene can adsorb lipophilic fractions from the suspending base, causing viscosity to increase by more than 20% over 6 months at 30°C. Therefore, high-density polyethylene bottles are specified with a barrier layer. Finished product types include 1 L, 2.5 L, and 5 L high-density polyethylene jerrycans with tamper-evident caps and graduated dosing chambers. Compliance standards are Ph. Eur. 2.9.27 for fill volume, Ph. Eur. 5.1.4 for microbiological quality, and VICH GL18 for residual solvents. The drench is intended only for oral administration; it is not formulated for use in automatic injection equipment.

Capsule filling with niclosamide for small-batch veterinary compounding or prescription dispensing uses 30–60% w/w API in a direct-fill powder blend. A size 2 hard capsule containing 125 mg niclosamide and 125 mg lactose monohydrate is filled on a 400-hole semi-automatic capsule machine at 4000–8000 capsules/hour. Above 60% w/w niclosamide, the blend Carr index exceeds 30, and capsule weight variation exceeds ±7.5% per Ph. Eur. 2.9.5. A 5 L V-blender is used with 2% w/w magnesium stearate added for the final 2 min of mixing; longer lubrication time reduces capsule dissolution. Dissolution testing follows Ph. Eur. 2.9.3, but the use of a fasting protocol in animals avoids the food-effect simulation that would otherwise be required. Regulatory compliance for compounded capsules falls under Ph. Eur. 2.9.40 and VICH GL18, while in EU member states pharmacy compounding may be governed by national pharmacopoeia chapters rather than Regulation (EU) 2019/6. Terminal product types include size 3, 2, and 0 hard hydroxypropyl methylcellulose capsules packed in 100-count white high-density polyethylene bottles with tamper-evident seals. Bovine-sourced gelatin capsules are avoided because niclosamide’s phenolic group can react with aldehydes in the capsule shell, causing cross-linking and a delayed dissolution profile. A production constraint is the API’s tendency to adhere to metal contact surfaces at RH >60%; therefore, encapsulation rooms are maintained at 35–45% RH.